Oruka Therapeutics Raises $700M at $72.50 After 64% Skin-Clearance Readout

NEW YORK, May 1 —

Oruka Therapeutics priced an upsized $700M stock offering at $72.50 a share, hours after Phase 2a data showed ORKA-001 cleared skin in 64% of plaque psoriasis patients at Week 16.

What Actually Happened

Oruka turned a clinical readout into a balance sheet event in about a day. The company pushed a marketed offering from $500M to $700M because the order book supported it. Biotechs upsize for one reason, and that's it. The hook is durability. ORKA-001 cleared skin in 64% of patients at Week 16, matching the IL-23 incumbents on efficacy. The differentiator is dosing: once a year, versus every eight weeks for the drugs patients take now. Same result, fewer shots, in a market as big as psoriasis. That's the category claim funding the raise.

The Catch

The stock is at $64.17. The deal cleared at $72.50. UBS sees $100. Those three numbers can't all be right, and the tape is siding with the lowest one. Call it the dilution overhang: the float just got bigger, and shares are drifting toward the price the new buyers paid, not where pre-deal holders had marked it. The Phase 2a result is one 16-week snapshot in moderate-to-severe patients. Phase 2b/3 has to repeat it. Biologics history is full of Week 16 winners that fade over longer trials against entrenched comparators.

Bottom Line

Oruka is more investable than it was a week ago. The $700M raise funds the company through the readouts that decide the franchise, and management didn't have to sell the company cheap to get there. The setup suits growth investors willing to absorb the dilution and wait for Phase 2b/3 to start. That's the next catalyst. Watch for updated cash runway guidance. That number tells you whether $700M buys two trials of dry powder or three.

No Basis Report exists yet for ORKA. Generate one at /stock/orka to see the full model.

Basis Report does not hold positions in securities discussed. This is not investment advice.